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Purpose: This study aimed to compare the incidence and clinical significance of 
transient versus persistent acute kidney injury (AKI) on acute ST elevation myocar-
dial infarction (STEMI). Materials and Methods: The study was a retrospective co-
hort of 855 patients with STEMI. AKI was defined as an increase of ≥0.3 mg/dL in 
creatinine level at any point during hospital stay. The study population was classified 
into 5 groups: 1) patients without AKI; 2) patients with mild AKI that was resolved 
by discharge (creatinine change less than 0.5mg/dL compared with admission creati-
nine during hospital stay, transient mild AKI); 3) patients with mild AKI that did not 
resolve by discharge (persistent mild AKI); 4) patients with moderate/severe AKI 
that was resolved by discharge (creatinine change more than 0.5 mg/dL compared 
with admission creatinine, transient moderate/severe AKI); 5) patients with moder-
ate/severe AKI that did not resolve by discharge (persistent moderate/severe AKI). 
We investigated 1-year all-cause mortality after hospital discharge for the primary 
outcome of the study. The relation between AKI and 1-year mortality after STEMI 
was analyzed. Results: AKI occurred in 74 (8.7%) patients during hospital stay. Ad-
justed hazard ratio for mortality was 3.139 (95% CI 0.764 to 12.897, p=0.113) in pa-
tients with transient, mild AKI, and 8.885 (95% CI 2.710 to 29.128, p<0.001) in pa-
tients with transient, moderate/severe AKI compared to patients without AKI. 
Persistent moderate/severe AKI was also independent predictor of 1 year mortality 
(hazard ratio, 5.885; 95% CI 1.079 to 32.101, p=0.041). Conclusion: Transient and 
persistent moderate/severe AKI during acute myocardial infarction is strongly relat-
ed to 1-year all cause mortality after STEMI.
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INTRODUCTION
Acute kidney injury (AKI) is a common complication in hospitalized patients, espe-
cially in high risk patients such as those hospitalized with acute myocardial infarc-
tion (AMI), congestive heart failure, sepsis, and those undergoing cardiac surgery.1-6 
Recent studies suggest that in patients with AMI, AKI is associated with poor out-
comes and independently predicts increasing in-hospital and long-term mortality.7-9 Min Jee Kim, et al.
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during hospitalization.; Group 1) Patients without AKI; 
Group 2) Patients with mild AKI that was resolved by dis-
charge (creatinine change less than 0.5 mg/dL compared 
with admission creatinine during hospital stay, transient 
mild AKI); Group 3) Patients with mild AKI that did not re-
solve by discharge (persistent mild AKI); Group 4) Patients 
with moderate/severe AKI that was resolved by discharge 
(creatinine change more than 0.5 mg/dL compared with ad-
mission creatinine, transient moderate/severe AKI); Group 
5) Patients with moderate/severe AKI that did not resolve 
by discharge (persistent moderate/severe AKI). 
Assessment of renal function
Laboratory data, including serum creatinine, was collected 
before coronary angiography on admission. Venous blood 
samples were obtained at 24, 48 and 72 hr thereafter. Pre-
discharge creatinine was measured on the day of discharge 
or the day before discharge. The abbreviated Modification 
of Diet in Renal Disease formula was used to estimate glo-
merular filtration rate (GFR) in milliliters per minute per 
1.73 m2 from creatinine level.17
Study endpoint
The primary endpoint was 1 year all cause mortality. After 
hospital discharge, clinical endpoint information was ac-
quired by contacting each patient individually and reviewing 
hospital course if the patient had been re-hospitalized.
Statistical assesment
Continuous variables are demonstrated as either means 
(±SD) or medians, and categorical variables as numbers and 
percentages. We compared baseline characteristics of the 
groups using analysis of variance (ANOVA) for continuous 
variables and by the χ2 statistic for categorical variables. Us-
ing Kaplan Meier method, event-free survival was estimated 
and curves were compared with log-rank test. To determine 
the relation between AKI categories and inhospital mortality, 
univariate and multivariate logistic regression analyses were 
examined. Univariate and multivariate Cox proportional haz-
ards analyses were used to assess the relationship between 
AKI categories and 1-year mortality after adjustments to the 
variables. Analyses were adjusted for age, gender, heart rate 
on admission, Killip class II-IV, estimated glomerular filtra-
tion rate, left ventricular ejection fraction, and medication 
(aspirin, beta blocker, angiotensin converting enzyme ACE 
inhibitors, and statin). A p value less than 0.05 was deemed 
as significant. Statistical analysis was done with the Statisti-
Previous investigations principally emphasized the rela-
tionship between baseline indicators of renal function and 
outcome.7,9-13 However, renal function during the acute phase 
of AMI may change rapidly and AKI can be resolved by 
discharge. In such patients, it is thought that AKI is not as-
sociated with high risk long-term follow up. By contrast, 
AKI after AMI can be partly or completely irreversible in 
some patients, resulting in profound impact on cardiovas-
cular outcomes. Few studies have examined the association 
between exacerbation of renal function and adverse clinical 
outcomes in patients with acute coronary syndrome. Fur-
thermore, the prognostic value of transient versus persistent 
AKI for acute ST elevation myocardial infarction (STEMI) 
is unknown in Korea. Therefore, the present study aimed to 
compare the incidence and clinical significance of transient 
versus persistent AKI on acute STEMI.
MATERIALS AND METHODS
　　　
Study population
This study was a retrospective cohort of consecutive 855 pa-
tients (62±13 years, men 75.2%) who were admitted to Chon-
nam National University Hospital and whose discharge diag-
nosis was acute STEMI by ACC criteria.14 Between October 
2005 and June 2008, a total of 921 patients presenting with 
acute STEMI were enrolled. To investigate the effects of AKI 
on the long term mortality, we excluded 66 patients who died 
during the hospital stay, and enrolled remaining 855 patients 
who were discharged from hospital in stable condition. On the 
other hand, to investigate the effects of AKI on the acute 
events, we analyzed in-hospital deaths separately to compare 
acute mortality according to AKI categories. 
   
Definition of AKI
The cutoffs for AKI were based on absolute creatinine chang-
es during hospitalization. AKI was defined as an increase of 
≥0.3 mg/dL in creatinine level at any point during hospital 
stay.15-16 The severity of AKI was subdivided on evidence 
from previous studies which showed that changes in creati-
nine level of at least 0.5 mg/dL are associated with increased 
mortality in patients with AMI.7,9,11 Mild AKI was defined 
as peak creatinine ≥0.3-0.49 mg/dL higher than baseline 
creatinine level, and moderate/severe AKI as an increase in 
serum creatinine ≥0.5 mg/dL compared with admission cre-
atinine at any point during the hospitalization. Patients were 
classified into 5 groups based on creatinine level changes Mortality of AKI in STEMI
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AKI; n=74, 8.7%). During the hospital course, mild AKI 
occurred in 38 (4.4%) patients and moderate/severe AKI in 
36 (4.2%). Mild AKI was transient in 28 (73.7%) patients, 
and moderate/severe AKI was transient in 22 (61.1%) pa-
tients. Table 1 and 2 list baseline clinical characteristics of 
patients based on AKI categories. More severe AKI during 
the hospital course was associated with older age, higher 
Killip class and heart failure (ejection fraction <45%). Pa-
tients with AKI had higher creatinine level at baseline, higher 
cal Package for the Social Sciences software (SPSS 17.0 for 
Windows, SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Baseline characteristics
Eight hundreds fifty five patients were included in the present 
study (patients without AKI: n=781, 91.3%, patients with 
Table 1. Baseline Clinical Characteristics 
No AKI (n=781)
Mild AKI Moderate/Severe AKI
p value
Transient (n=28) Persistent (n=10) Transient (n=22) Persistent (n=14)
Age (yrs)   61±13   68±12   65±14 71±7 65±14 <0.001
Male gender (%)  588 (75.3) 18 (64.3) 10 (100) 15 (68.2) 12 (85.7)   0.165
Hypertension (%) 343 (43.9) 16 (57.1) 5 (50) 14 (63.6) 7 (50)   0.252
Smoking (%) 529 (67.7) 17 (64.3) 10 (100) 13 (59.1) 8 (57.1)   0.146
Diabetes (%) 195 (25.0) 7 (25) 5 (50)   8 (36.4) 5 (35.7)   0.252
Dyslipidemia (%) 31 (3.9) 0 (0) 0 (0) 0 (0) 0 (0)   0.550
CAD History (%) 58 (7.4)   4 (14.3) 3 (30)   3 (13.6) 2 (14.3)   0.043
Killip class II-IV (%) 128 (16.4)    12 (42.9) 3 (30) 11 (50) 5 (35.7) <0.001
SBP (mmHg) 131±30 138±33 124±22 120±41 91±55   0.100
HR (beats/min)   75±17   88±18   78±14   72±29 75±18   0.003
EF (%)   55±12   53±15   53±11   46±12 41±15 <0.001
Hospital length (days)   9±8   14±10 10±4   22±18 25±39 <0.001
AKI, acute kidney injury; SBP, systolic blood pressure; CAD, coronary arterial disease; EF, ejection fraction; HR, heart rate.
Table 2. Baseline Kidney Function, Medical History and Major Adverse Cardiac Event 
No AKI (n=781)
Mild AKI Moderate/Severe AKI
p value
Transient (n=28) Persistent (n=10) Transient (n=22) Persistent (n=14)
Kidney function
    Serum Cr (mg/dL) 1.07±0.98 1.02±0.35     1.3±1.67 1.38±0.53 2.39±1.91 <0.001
    Estimated GFR 
      (mL/min/m
2)*
82.6±24.4 77.2±25.0 121.4±90.1 58.0±24.2   80.6±136.6 <0.001
    Peak Cr (mg/dL) 0.98±0.52 1.35±0.36   1.64±1.66 2.32±0.65 3.75±2.69 <0.001
Medications (%)
    Aspirin  761 (97.4) 26 (92.9) 9 (90) 22 (100) 14 (100)   0.267
    Beta blocker 638 (81.7) 22 (78.6) 8 (80) 14 (63.6) 10 (71.4)   0.241
    Statin 674 (86.3) 26 (92.9) 6 (70) 16 (72.7) 10 (71.4)   0.027
    ACE inhibitor/ARB 706 (90.4) 27 (96.4) 7 (80) 14 (63.6) 12 (85.7) <0.001
Major adverse cardiac event (%)
    MACE 106 (13.6)   3 (10.7) 2 (20)   7 (31.8)   5 (14.3)   0.021
    Cardiac death   9 (1.2) 0 (0) 1 (10)   5 (22.7)   2 (14.3) <0.001
    All-cause death 16 (2.0) 1 (3.6) 1 (10)   6 (27.3)   2 (14.3) <0.001
    Re-PCI   80 (10.2) 1 (3.6) 1 (10) 1 (4.5) 1 (7.1)   0.698
    CABG   2 (0.3) 0 (0) 0 (0) 0 (0) 0 (0)   0.996
Treatment strategy
    Primary PCI 536 (68.6) 21 (75) 7 (70) 17 (77.3) 10 (71.4)   0.867
    Thrombolysis 114 (14.6) 2 (7.2) 0 (0) 0 (0) 1 (7.1)   0.064
    Conservative treatment  67 (8.6) 1 (3.6) 1 (10)   4 (18.2)   3 (21.4)   0.128
AKI, acute kidney injury; GFR, Glomerular filtration rate; Cr, creatinine; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers; MACE, 
major adverse cardiac event; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft. 
*On the basis of abbreviated MDRD (Modification of Diet in Renal Disease) study equation.Min Jee Kim, et al.
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moderate/severe AKI was associated with a statistically sig-
nificant increase of inhospital mortality. However, after ad-
justment for other risk variables, there was no association 
with AKI categories and in hospital mortality.
Relation of AKI and 1 year mortality 
The median duration of follow-up after hospital discharge 
was 358 days. Of the 855 patients who survived their index 
hospitalization, a total of 25 (2.9%) deaths occurred during 
the follow-up period. Fig. 1 illustrates Kaplan-Meier survival 
in patients with AKI groups during follow-up. The Kaplan-
Meier survival curves for the AKI groups showed signifi-
cant differences of 1-year mortality after hospital discharge 
statistically. In each of the AKI groups, persistent moderate/
severe AKI group showed lower probability of event-free 
survival compared with the other groups. Also, during the 
follow-up period, probability of death increased with in-
creasing degrees of AKI. 
The results of a multivariable cox proportional hazards 
model adjusting for other clinical variables of mortality are 
shown in Table 3 and 4. After adjustments for other risk 
variables including baseline estimated GFR and other clini-
cal variables, there was no differences in 1-year mortality 
risk between transient mild AKI group and group without 
AKI. On the other hand, transient moderate/severe AKI 
was associated with an adjusted hazard ratio of 8.885 com-
peak creatinine during the hospital course, present with 
lower ejection fraction compared with the patients without 
AKI. Use of statin, angiotensin converting enzyme inhibi-
tors or angiotensin receptor blockers was less frequent in 
more severe AKI. However, estimated GFR was the lowest 
in the group with transient moderate/severe AKI.
Relation of AKI and inhospital mortality 
A total of 66 (7.2%) deaths occurred in hospital, with 25 
(37.9%) deaths occurring in patients with acute kidney in-
jury. Univariate logistic regression showed that persistent 
Table 3. Unadjusted and Adjusted Logistic Regression Model for Inhospital Mortality According to Acute Kidney Injury Cat-
egories  
Unadjusted OR (95% CI) p value Adjusted OR (95% CI) p value
Normal <0.001 0.186
Transient mild AKI     0.77 (0.102-5.818)   0.800   0.273 (0.021-3.578) 0.323
Persistent mild AKI   2.156 (0.269-17.299)   0.470 12.445 (0.847-182.901) 0.066
Transient moderate/severe AKI     1.96 (0.444-8.657)   0.375   0.368 (0.038-3.595) 0.390
Persistent moderate/severe AKI 32.333 (15.208-68.745) <0.001   2.087 (0.430-10.121) 0.361
AKI, acute kidney injury; CI, confidence interval.
Table 4.  Unadjusted and Adjusted Logistic Regression and Cox Proportional Hazards Model for Mortality According to Acute 
Kidney Injury Categories*
No AKI
Mild AKI Moderate/Severe AKI
Transient Persistent Transient Persistent
Inhospital mortality (p value)
    Unadjusted logistic           <0.001 0.800 0.470   0.375 <0.001
    Adjusted logistic               0.186 0.323 0.066   0.390   0.361
1-yr mortality (p value)
    Unadjusted cox              <0.001 0.003 0.084 <0.001   0.003
    Adjusted cox                   0.005 0.113 0.987 <0.001   0.041
AKI, acute kidney injury; CI, confidence interval.
*The final model adjusted for age, gender, estimated glomerular filtration rate, history of hypertension, diabetes, smoking, previous myocardial infarction, 
Killip class, heart rate and blood pressure on admission, medical therapy (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers) and 
left ventricular ejection fraction.
Fig.1. Kaplan-Meier survival curves according to acute kidney injury cate-
gories. AKI, acute kidney injury.
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Differences may be attributed to different races, measure-
ment methods of serum creatinine and enrolled size.
Previous investigators have demonstrated that baseline 
renal dysfunction or CKD is associated with poor outcomes 
during short and intermediate-term follow up after AMI20-24 
or acute coronary syndromes.25-27 The present study showed 
transient and persistent moderate/severe AKI as a risk fac-
tor for all cause mortality after STEMI. This means that 
worsening renal dysfunction and baseline renal dysfunction 
specifically define a group at a very high risk for mortality 
and may reflect underlying mechanisms that adversely af-
fect both cardiac and renal function.7 
AKI is a complex multifactorial phenomenon, precondi-
tioned by underlying renal dysfunction and modulated by 
multiple contributing factors.28 For example, neurohormon-
al factors,29 such as norepinephrine, rennin-angiotensin, va-
sopressin, and endothelin, may affect renal function and 
play a role in renal dysfunction, modulating post infarct left 
ventricular remodeling.30-32 Also, volume depletion, the use 
of contrast media,33 and medical treatment such as diuretics 
or angiotensin converting enzyme inhibitors or angiotensin 
receptor blocker may affect renal dysfunction in reversible 
manner. Even though these factors may affect renal func-
tion and the outcomes of AMI, there are few studies regard-
ing the incidence and clinical impact of transient versus per-
sistent AKI in patients with AMI. Therefore, understanding 
the impact of transient versus persistent AKI on acute mor-
tality and long-term outcomes is expected to assist with guid-
ing follow up care for patients with acute myocardial infarc-
tion after discharge. 
There are several points to be considered. Other predic-
tors of AKI, such as current pharmacologic and procedural 
interventions for therapy of AMI that may be helpful to the 
heart but affect renal dysfunction, need to be considered.9 
Furthermore, it has to be considered other types of thera-
peutic managements that can be applied to these patients to 
decrease the risk of mortality after AKI. AKI occurrences in 
MI patients should be monitored for given the increased 
risk of long-term death. Patients with AKI should be care-
fully monitored after discharge for potential development 
of related complications. Our study has several limitations. 
Because of methodological limitations inherent in retrospec-
tive analyses, our data cannot include the volume of contrast. 
Therefore, we did not address the influence of contrast vol-
ume that was administered during percutaneous coronary 
intervention. In addition, patients with poorer general con-
dition are more likely to have longer hospitalizations and, 
pared with group without AKI. Patients with persistent mod-
erate/severe AKI had the highest all-cause of mortality com-
pared with other groups (hazard ratio, 5.885; 95% CI 1.079 
to 32.101, p=0.046). 
DISCUSSION
In the present study, AKI occurred in 74 (8.7%) patients 
during hospital course with STEMI who survived their in-
dex hospitalization. After acute stage of myocardial infarc-
tion, improvement of renal function within the index hospi-
talization revealed 73.7% of patients in mild AKI and 61.1% 
of patients in moderate/severe AKI. Patients developing 
AKI have worse baseline renal function and are more likely 
to present higher peak serum creatinine level. Baseline esti-
mated GFR was the lowest in transient moderate/severe 
AKI group and peak serum creatinine was the highest in 
persistent moderate/severe AKI group. More severe AKI 
group showed longer hospital lengths. It is thought that 
there were more combined complications in severe AKI. 
Furthermore, in patients with transient mild AKI and tran-
sient moderate/severe AKI, there was no association with 
prognostic significance of 1-year all cause mortality after 
STEMI. Especially in mild transient AKI group, outcome 
of the group was similar to that of patients without AKI. Al-
though it did not completely exclude absolute impacts and 
many questions about the relationship between renal dys-
function and mortality after AMI, several studies suggested 
that increment of serum creatinine level during admission is 
a significant independent predictor of mortality, especially 
in the setting of decompensated heart failure2,18 and AMI.19 
However, our result showed that transient mild AKI did not 
affect long-term mortality in STEMI. In patients with mild 
transient AKI and moderate/severe transient AKI, there was 
no association with prognostic significance of 1-year all 
cause mortality, suggesting that transient mild or moderate/
severe AKI represent a reversible renal impairment and do 
not affect long term mortality if corrected. 
To investigate the effects of AKI on the acute events, we 
analyzed inhospital deaths separately according to acute kid-
ney injury categories, and found that AKI has no association 
with inhospital mortality after adjustment for clinical predic-
tors of mortality among patients with STEMI. These findings 
suggest that impaired renal function after STEMI is an inde-
pendent predictor of 1-year mortality, but not of inhospital 
mortality. These observations are different from other study.7 Min Jee Kim, et al.
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ease: results from the cooperative cardiovascular project. Am J 
Kidney Dis 2000;35:1044-51.
12. Brown JR, Cochran RP, Dacey LJ, Ross CS, Kunzelman KS, Dun-
ton RF, et al. Perioperative increases in serum creatinine are pre-
dictive of increased 90-day mortality after coronary artery bypass 
graft surgery. Circulation 2006;114:I409-13.
13. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, 
et al. Immediate postoperative renal function deterioration in car-
diac surgical patients predicts in-hospital mortality and long-term 
survival. J Am Soc Nephrol 2005;16:195-200.
14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarc-
tion redefined--a consensus document of The Joint European So-
ciety of Cardiology/American College of Cardiology Committee 
for the redefinition of myocardial infarction. J Am Coll Cardiol 
2000;36:959-69.
15. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock 
DG, et al. Acute Kidney Injury Network: report of an initiative to 
improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute 
Dialysis Quality Initiative workgroup. Acute renal failure - defini-
tion, outcome measures, animal models, fluid therapy and infor-
mation technology needs: the Second International Consensus 
Conference of the Acute Dialysis Quality Initiative (ADQI) Group. 
Crit Care 2004;8:R204-12.
17. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney func-
tion--measured and estimated glomerular filtration rate. N Engl J 
Med 2006;354:2473-83.
18. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Wat-
nick SG, et al. Worsening renal function: what is a clinically mean-
ingful change in creatinine during hospitalization with heart fail-
ure? J Card Fail 2003;9:13-25.
19. Bouzas-Mosquera A, Vázquez-Rodríguez JM, Peteiro J, Alvarez-
García N. Acute kidney injury and long-term prognosis after acute 
myocardial infarction. Arch Intern Med 2009;169:87.
20. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, 
Dvorak DL, et al. Acute myocardial infarction and renal dysfunc-
tion: a high-risk combination. Ann Intern Med 2002;137:563-70.
21. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, 
Wiviott SD, et al. Association of creatinine and creatinine clear-
ance on presentation in acute myocardial infarction with subse-
quent mortality. J Am Coll Cardiol 2003;42:1535-43.
22. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lan-
sky AJ, et al. Impact of renal insufficiency in patients undergoing 
primary angioplasty for acute myocardial infarction. Circulation 
2003;108:2769-75.
23. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner 
WS, McClellan MB. Association of renal insufficiency with treat-
ment and outcomes after myocardial infarction in elderly patients. 
Ann Intern Med 2002;137:555-62.
24. Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-
Jones DM. Elevated serum creatinine is associated with 1-year 
mortality after acute myocardial infarction. Am Heart J 2002;144: 
1003-11.
25. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, 
Califf RM, et al. Prognostic implications of abnormalities in renal 
function in patients with acute coronary syndromes. Circulation 
2002;106:974-80.
hence, performed more frequent renal function studies in-
cluding blood sampling, thus there has been the increasing 
probability of serum creatinine level change detection.
In conclusion, the present study shows that hemodynam-
ic changes in renal function are common in AMI that is as-
sociated with long term mortality, especially in transient and 
persistent moderate/severe AKI.
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